1. Scrip
  2. >>Focus On Asia

Next Allergy Blockbuster? GI Innovation Shares Why It Is Confident

CEO Aims For Korean Commercialization Model

 
• By Jung Won Shin

GI Innovation chairman and CEO B G Rhee talks about his ambitions for the Korean bispecific protein firm’s leading allergy and immuno-oncology pipeline assets and what is behind his confidence.

BG Rhee, Chairman & CEO of GI Innovation
'We Are Not Competing With Xolair,' GI Innovation's CEO says • Source: GI Innovation

The South Korean biotech industry has advanced substantially over the past decade, with an increasing number of major global out-licensing deals. But despite these achievements, none of the assets involved has actually reached the marketing stage yet.

“So far, nothing really has been commercialized

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.